Johnson & Johnson Presents New Data Showing Long-Term Sustained Disease Control With Investigational Nipocalimab In Adults With GMG
Express News | J&J- Results Show 18 Months of Sustained Reduction in Immunoglobulin G Antibodies & Sustained Improvement in Gmg Symptoms
Express News | J&J - up to 128 Weeks & 180 Patient Years of Follow-up in Open-Label Extension(a) Confirm Safety Profile Consistent With Phase 3 Vivacity-Mg3 Study
Express News | Johnson & Johnson Highlights New Data That Showcase the Strength of Nipocalimab, Demonstrating Long-Term Sustained Disease Control in Adults Living With Generalized Myasthenia Gravis (Gmg)
Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference
Unusual Options Activity: OWL, NCLH and Others Attract Market Bets, OWL V/OI Ratio Reaches 768.9
